Remove DNA Remove Genomics Remove In-Vitro
article thumbnail

BMS’s repotrectinib to have FoundationOne genomic sequencing companion diagnostic

Pharmaceutical Technology

FoundationOne CDx is a sequencing-based in vitro diagnostic device that can identify alterations in 324 genes from tumour samples. With advances in DNA sequencing, such as the technology developed by Foundation Medicine, the genetic profiles of lung cancer patients could be annotated to then select appropriate treatment options.

Genomics 130
article thumbnail

Artificial Intelligence innovation: Leading companies in in-silico drug discovery

Pharmaceutical Technology

Within the emerging innovation stage, DNA chips, tissue culturing automation, and mass spectrometry analysis are disruptive technologies that are in the early stages of application and should be tracked closely. However, not all innovations are equal nor do they follow a constant upward trend.

Drugs 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research

The Pharma Data

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. Cancer is a disease of the genome and treatment no longer depends solely on the tissue of origin.

article thumbnail

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation.

Genomics 119
article thumbnail

Top 30 New Medical Devices of 2024

XTalks

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. In this blog, we discuss some of these new medical devices of 2024 that have improved patient outcomes and enhanced quality of life worldwide.

article thumbnail

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

The Pharma Data

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

article thumbnail

BMS joins forces with insitro to develop neurodegenerative treatments

pharmaphorum

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.